Cross-Cultural Validation of the RECAP of Atopic Eczema Question­naire in a Swedish Population

• Main Authors: Gunnthorunn Sigurdardottir (Author), Mikael Alsterholm (Author), Chris D. Andersson (Author), Maria Bradley (Author), MariHelen Sandström Falk (Author), Emma K. Johansson (Author), Maria Lundqvist (Author), Andreas Sonesson (Author), Åke Svensson (Author), Grigorios Theodosiou (Author), Sophie Vrang (Author), Laura B. von Kobyletzki (Author)
• Format: Book
• Published: Medical Journals Sweden, 2024-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

A Swedish translation of the patient-reported outcome measure for assessing long-term control of atopic dermatitis, Recap of atopic eczema (RECAP), has not been validated. Cross-cultural translation and multi-centre validation of the translated RECAP questionnaire were therefore performed. Disease severity was assessed using the validated Investigator Global Assessment Scale for atopic dermatitis (vIGA-ADTM). The Swedish RECAP was completed by 208 individuals aged 16 years or older with a median age of 36 years (interquartile range [IQR] 27-48). The participants considered the questionnaire suitable for assessing eczema control. The median RECAP score (range 0-28) was 12 (IQR 5-19). The mean and median vIGA-ADTM scores (range 0-4) were 2 (standard deviation [SD] 2) and 3 (IQR 2-4), respectively. A correlation between RECAP and the vIGA-ADTM was observed (p < 0.001). There was no significant change in scores for participants who answered the questionnaire twice within 14 days. Over time, improved or worsened eczema, as evaluat-ed by vIGA-ADTM, affected RECAP scores significantly (p < 0.001). The study suggests that RECAP can assess AD control in a Swedish clinical setting and shows -acceptable reliability.

Item Description

10.2340/actadv.v104.38889
0001-5555
1651-2057